The HeartMate III MOMENTUM 3 Trial Showed Better Two-Year Outcomes Than Its Predecessor. Here Is What That Means.

The Scene

The man has spent the last six months losing weight he cannot afford to lose. He is 61 years old, a retired plumber from Decatur, Illinois, and his heart failure has been progressive since his second MI four years ago. His LVEF is 12%. He is on maximum medical therapy: sacubitril/valsartan, carvedilol 25 mg twice daily, spironolactone, furosemide. He has a CRT-D. He has been hospitalized three times in the last five months for volume overload. The last hospitalization required IV milrinone for 72 hours before his right heart catheterization numbers recovered enough to discharge him. His cardiac output at the last right heart catheterization was 2.8 liters per minute. His pulmonary capillary wedge pressure was 29 mmHg. His creatinine is 2.1 and rising.

His cardiologist in Decatur has referred him to the advanced heart failure program at the University of Illinois Hospital in Chicago. The advanced heart failure team there evaluates him over two days of inpatient testing. He is INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profile 3: stable on oral inotropes, unable to wean, progressive symptoms. He is listed for cardiac transplant but his blood type is O-negative, his panel reactive antibody is low, and the median wait time in his UNOS region for a donor heart is 18 months. He is unlikely to survive 18 months on his current trajectory.

The team presents him with a choice: implantation of a left ventricular assist device, specifically the HeartMate III (Abbott), as a bridge to transplantation. The device will not cure his heart failure. It will do what his left ventricle cannot: pump blood forward continuously, reduce the filling pressures that are destroying his kidneys and liver, allow his body to recover enough function that he will be stronger when the transplant happens.

His wife asks how long people live with this machine. The answer is honest: the majority of patients who receive the HeartMate III reach two years of support with adequate quality of life 5 / Solid . Some live more than five years on the device. Some receive it as destination therapy with no transplant planned. He will carry a driveline through his abdomen. He will charge a controller every night. He will wear a vest with batteries when he leaves the house. He will not swim. He will not take a bath. He will check the device display every morning the way he currently checks his blood pressure.

He agrees to the implant.

What It Is

The HeartMate III is a fully magnetically levitated centrifugal-flow left ventricular assist device (LVAD) manufactured by Abbott (formerly Thoratec Corporation). It is surgically implanted to assume the pumping function of the failing left ventricle, drawing blood from the left ventricular apex and ejecting it into the ascending aorta, bypassing the diseased left ventricular muscle entirely.

The HeartMate III is the current generation of LVAD technology. Its two predecessors in the HeartMate line were:

• HeartMate I (HeartMate XVE): a pulsatile, pneumatically driven displacement pump, FDA-approved in 1994 for bridge to transplant and in 2003 for destination therapy. It had a large footprint, noisy operation, and short device durability.
• HeartMate II: an axial-flow pump (the impeller spins along the axis of blood flow), FDA-approved in 2008 for bridge to transplant and in 2010 for destination therapy. The HeartMate II dramatically improved durability and miniaturization but had a significant rate of pump thrombosis (clot formation on the impeller bearing).
• HeartMate III: centrifugal-flow pump with full magnetic levitation of the impeller (no mechanical bearing contact), FDA PMA approval in 2017 for bridge to transplant and destination therapy.

Competing LVAD platforms include the HeartWare HVAD (Medtronic), which was voluntarily withdrawn from the market in June 2021 due to neurological event rates and restart failure issues (discussed in DEVI-017), making the HeartMate III the dominant LVAD platform in the United States as of 2026.

The HeartMate III is regulated as a Class III medical device under FDA Premarket Approval (PMA), the highest FDA regulatory class, requiring clinical trial evidence of safety and effectiveness prior to market authorization.

The Mechanism

3.1 How the Failing Heart Loses Output

The left ventricle, in advanced systolic heart failure, loses its ability to generate the pressure differential required to eject blood into the aorta against systemic vascular resistance. The Frank-Starling mechanism initially compensates, but as the myocardium dilates, filling pressures rise, the pericardium constrains further dilation, and the right ventricle must pump into a chronically congested pulmonary circuit. The cascade: raised left atrial pressure, raised pulmonary capillary wedge pressure, pulmonary hypertension, right ventricular strain, hepatic congestion (cardiohepatic syndrome), renal hypoperfusion (cardiorenal syndrome), and eventually end-organ failure.

The LVAD addresses this cascade not by repairing the myocardium but by mechanically supplementing its output.

3.2 The Centrifugal-Flow Architecture

The HeartMate III uses a centrifugal pump: the impeller (a spinning disc with vanes) accelerates blood radially outward from the center to the periphery, generating pressure from rotational kinetic energy rather than displacement volume. The impeller is suspended by full magnetic levitation (using electromagnetic forces from the stator): there are no mechanical bearings, no shaft, no physical contact between the impeller and the pump housing during normal operation.

The key clinical advantages of full magnetic levitation:

1. Zero mechanical wear at the bearing surfaces (because there are no mechanical bearings): the main failure mode of previous LVAD generations (bearing degradation) is eliminated. Long-term device durability is substantially improved.
2. Wider blood flow gaps between impeller and housing: reduces shear forces on red blood cells and platelets, decreasing hemolysis and potentially reducing pump thrombosis rates.
3. Artificial pulse generation: the HeartMate III is programmed to modulate its rotational speed (up and down by 2,000 rpm in a sinusoidal pattern over a period of approximately 2 seconds) to create an artificial pulse waveform despite continuous-flow operation. This pulsatility algorithm was designed to reduce the risk of aortic valve fusion from chronic closure (a complication of continuous-flow LVADs where the aortic valve never opens because the LVAD provides all forward flow).

3.3 The Driveline and External Components

The pump is implanted in the pericardial space. An inflow cannula passes through the apex of the left ventricle into the left ventricular cavity. An outflow graft is anastomosed to the ascending aorta. A driveline, a percutaneous cable approximately 1 cm in diameter, tunnels through the abdominal wall and connects the internal pump to the external controller and battery system.

The external system consists of:

• System controller (approximately 300 g): worn on a belt or shoulder strap. Displays pump speed, power consumption, flow estimate, pulsatility index, and alarm status.
• Batteries (two batteries, each approximately 500 g): provide 4 to 6 hours of operation per pair. Patients typically carry two sets.
• Power module (for bedside/home use): connects to a wall outlet and eliminates battery use overnight.

The driveline exit site is the most clinically important chronic care issue. The driveline passes through skin, and the skin interface is permanently compromised: it cannot heal normally because a foreign body is always present. Driveline infections are the most common and most serious chronic complication of LVAD therapy, occurring in 18 to 30% of patients over 2 years of support 5 / Solid .

How It Is Used

4.1 INTERMACS Profiles and Patient Selection

The INTERMACS classification system, developed for standardized reporting of mechanical circulatory support outcomes, stratifies advanced heart failure patients into seven profiles from most to least critically ill:

The HeartMate III performs best in INTERMACS profiles 2 to 4, where the patient is ill enough to benefit from support but not so critically ill that the implant carries excessive operative mortality. Profile 1 patients (cardiogenic shock) have high operative mortality for LVAD implantation and are often bridged with ECMO or Impella first to stabilize before the definitive LVAD implant.

4.2 Bridge to Transplant vs. Destination Therapy

LVADs are implanted in one of two strategic contexts:

Bridge to transplant (BTT): the patient is listed for cardiac transplant, and the LVAD supports them until a donor heart becomes available. In the current era of organ shortage (median wait time 12 to 24 months in most U.S. UNOS regions), BTT is the most common use at transplant centers. The goal is to optimize the patient’s end-organ function, nutritional status, and functional capacity over the months of LVAD support so that the transplant occurs with the best possible recipient status.

Destination therapy (DT): the patient is not a transplant candidate (due to age, comorbidities, or patient preference) and the LVAD is the permanent treatment. With the HeartMate III showing 2-year outcomes now equivalent to those after cardiac transplantation in select populations, the boundary between DT and permanent LVAD therapy is increasingly the standard of care for older patients with advanced heart failure who are not transplant candidates 5 / Solid .

4.3 Anticoagulation and Drug Management

All continuous-flow LVADs, including the HeartMate III, require lifelong anticoagulation with warfarin (target INR 2.0 to 3.0) and antiplatelet therapy with aspirin (81 mg daily). The combination is required because the pump, inflow cannula, and outflow graft are all thrombogenic surfaces, and clot formation within the device causes pump thrombosis, which can manifest as hemolysis (LDH elevation), device failure, or thromboembolism. Despite the advances of full magnetic levitation in the HeartMate III, anticoagulation remains required.

The bleeding complications from lifelong anticoagulation in an LVAD patient are significant. Gastrointestinal bleeding is the most common adverse event, occurring in 18 to 20% of patients per year, driven in part by acquired von Willebrand disease: the high-shear forces within the continuous-flow pump cleave large von Willebrand factor multimers, reducing platelet aggregation and increasing bleeding risk from arteriovenous malformations that develop in the intestinal mucosa under chronic heart failure 5 / Solid .

The Evidence

5.1 MOMENTUM 3: The Landmark Trial

The MOMENTUM 3 trial (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) enrolled 1,028 patients and randomized them 1:1 to the HeartMate III (centrifugal, fully maglev) versus the HeartMate II (axial-flow) 5 / Solid .

At 2 years:

The HeartMate III demonstrated a dramatic reduction in pump thrombosis and a significant reduction in disabling stroke compared to the HeartMate II. The primary endpoint improvement was driven by both outcomes. This trial established the HeartMate III as the standard of care and led to the effective clinical replacement of the HeartMate II.

5.2 Two-Year Survival vs. Cardiac Transplant

In the subset of MOMENTUM 3 destination therapy patients, 2-year survival with the HeartMate III was 76.9%, comparable to outcomes after cardiac transplantation for appropriately selected older patients 4 / Promising . This comparison is not an RCT (transplant vs. LVAD were not randomized); it reflects the evolution of both modalities and the argument that DT-LVAD in patients over 65 may have outcomes approaching transplant without the scarcity of donor hearts.

5.3 Gastrointestinal Bleeding: The Persistent Burden

Despite the HeartMate III’s improvements in thrombotic outcomes, GI bleeding rates have not declined proportionally. A pooled analysis of contemporary LVAD registries found GI bleeding rates of approximately 19 to 22% per patient-year, driven by acquired von Willebrand disease and the high prevalence of arteriovenous malformations in the gut mucosa 5 / Solid . Management involves modifying the anticoagulation target during active bleeding, endoscopic therapy, and consideration of octreotide for recurrent AVMs. Reducing or temporarily stopping warfarin during active GI bleeding must be balanced against device thrombosis risk: this is one of the most challenging management decisions in LVAD care.

5.4 Right Heart Failure After LVAD

Right ventricular failure after LVAD implantation occurs in approximately 10 to 20% of patients and is the most common cause of early post-implant death 5 / Solid . The mechanism: when the LVAD decompresses the left ventricle and increases its output, the additional volume presented to the right ventricle may overwhelm a diseased right heart. The interventricular septum, which was supporting the right ventricle through its contribution to the common ventricular chamber, may shift leftward after LVAD decompression, worsening RV geometry and function (ventricular interdependence).

Preoperative RV function assessment, including right heart catheterization hemodynamics (RVSWI, RAP/PCWP ratio), is a critical part of LVAD candidacy evaluation. Patients with severe baseline RV dysfunction may require temporary right-sided MCS (Impella RP, ECMO, or temporary RVAD) as a bridge through the post-implant RV failure period.

The Patient Experience

6.1 The First 30 Days

The HeartMate III implant requires median sternotomy and cardiopulmonary bypass. The operation takes 4 to 6 hours. The patient wakes in the cardiac surgery ICU. The first two weeks are dominated by fluid management, respiratory recovery, and right ventricular support if needed. The driveline exit site is placed low on the right abdominal wall, positioned to minimize infection risk and allow the patient to care for it independently.

At 2 to 3 weeks, if recovery is uncomplicated, the patient begins LVAD coordinator training. This is not optional. The patient and one or two designated caregivers (the LVAD team calls them the “power of two”) must learn: daily device checks, battery charging and exchange, driveline site care, alarm response protocols, and what to do in specific emergencies (loss of power, controller alarm, suction alarm indicating inadequate LV filling).

The LVAD coordinator at the implanting center, typically an advanced practice provider with specialized LVAD training, becomes the patient’s primary point of ongoing contact. LVAD patients are seen in clinic monthly or bimonthly during the first year, with device interrogation, laboratory monitoring (LDH to screen for pump thrombosis, INR for anticoagulation), and functional assessment at each visit.

6.2 Daily Life With an LVAD

The retired plumber from Decatur goes home six weeks after implant. He has gained four kilograms since the operation, all of it muscle mass and restored volume that his kidneys are now managing. His creatinine has improved to 1.4. He takes showers with a specialized waterproof driveline dressing. His wife has learned to change the dressing. He cannot swim, cannot submerge the driveline, and will not take a bath. He checks his controller display every morning before coffee.

His heart rate, measured at the wrist, is often imperceptible. The HeartMate III runs continuously; unless the aortic valve opens (which it may not, especially at higher speeds), the peripheral pulse can be faint or absent. Blood pressure measurement requires a Doppler probe rather than a standard cuff in some patients, because the Korotkoff sounds generated by intermittent flow may not be audible.

He returns to Decatur 8 weeks after discharge. His local cardiologist is copied on every visit note from the LVAD program. A telemedicine check-in occurs biweekly for the first 3 months. His INR is monitored weekly by his local anticoagulation clinic.

He is alive and functional at 18 months. He is still waiting for a donor heart.

6.3 Driveline Infection Management

Driveline infections are classified by depth:

• Superficial (skin level): oral antibiotics, enhanced wound care, possibly silver dressing. Rarely progresses.
• Deep driveline infection (to the level of the abdominal fascia or pump pocket): intravenous antibiotics, often chronic suppressive therapy. If the pump pocket is infected, device exchange may be required but carries high mortality.

Prevention is the primary strategy: securing the driveline to minimize motion at the skin exit site (the “driveline stabilization” suture and vest system), maintaining strict exit site care, and educating patients not to pull on or move the driveline.

6.4 Sex Differences

Women are substantially underrepresented in LVAD implantation, comprising approximately 20 to 25% of recipients in most registries, despite representing nearly 50% of the advanced heart failure population 4 / Promising . Multiple factors contribute: nonischemic cardiomyopathy (more common in women) has a different natural history than ischemic cardiomyopathy, women may be referred for advanced heart failure evaluation later in their disease course, and smaller body habitus in some women creates anatomical constraints for device positioning. Women who do receive LVADs have higher rates of post-operative RV failure and bleeding complications but similar or better 2-year survival compared to men in the MOMENTUM 3 subgroup analyses.

Decisions and Trade-Offs

7.1 The Transplant vs. Destination Therapy Decision

For a 61-year-old man on the transplant waitlist, the strategic question is whether the LVAD is a bridge to a better destination (transplant) or is itself the destination. If transplant occurs, the LVAD is explanted. If the patient ages out of transplant candidacy (some programs have an upper age cutoff of 65 to 70), accumulates comorbidities that preclude transplant, or simply waits too long, the LVAD becomes permanent.

The honest framing for the patient at implant: “We are implanting this as a bridge to transplant, but we want you to understand that if circumstances change and transplant is no longer possible, this device will continue to support you for years.”

7.2 Quality of Life Data

Quality of life data from MOMENTUM 3 and related registries consistently show significant improvement from pre-LVAD to 3 to 6 months post-implant: 6-minute walk distance increases from approximately 180 m to 340 m, Minnesota Living With Heart Failure scores improve substantially, and NYHA class shifts from predominantly IV to predominantly II 5 / Solid . These gains plateau at 6 months and are maintained at 2 years.

The gains are real. But they come with the permanent obligation of device management: the batteries, the driveline care, the INR monitoring, the travel restrictions (no international travel without a plan for battery supply and emergency LVAD support access), the psychological weight of knowing the device is always running and always necessary.

7.3 The Decision to Deactivate

LVAD deactivation is medically and ethically equivalent to withdrawing any other life-sustaining treatment. A patient with terminal cancer, advanced dementia, or irreversible multiorgan failure who requests LVAD deactivation has the same right to that request as a patient on a ventilator who requests extubation. This conversation is one of the most difficult in advanced heart failure care, but it must occur proactively, not at the time of a crisis.

The Heart Failure Society of America and the AHA Heart Failure guidelines both address end-of-life LVAD management explicitly. The ACC/AHA/HRS consensus statement on device deactivation supports the patient’s right to request LVAD deactivation at any time 5 / Solid .

7.4 Cost and Access

The HeartMate III hardware costs approximately $80,000 to $100,000 (device only), with total hospitalization costs for LVAD implantation (including the operation, ICU, hospital stay, and post-discharge coordination) typically exceeding $200,000. These costs are covered by Medicare and most major commercial insurers for appropriately indicated patients, with prior authorization requirements. CMS reimbursement approval requires implantation at a certified LVAD center.

LVAD implantation is performed only at advanced heart failure/transplant centers. In Illinois, these include Northwestern Memorial Hospital, University of Chicago Medical Center, Rush University Medical Center, and University of Illinois Hospital in Chicago, along with loyola University Medical Center and Advocate Christ Medical Center. Patients in central and southern Illinois typically require referral and relocation to Chicago for the implant and the intense first 3 months of follow-up, after which they may transition to local cardiologist co-management with telemedicine LVAD program support.

Clinical Synthesis

The HeartMate III LVAD represents the definitive end stage of the preventable heart disease trajectory that preventive cardiology exists to interrupt. The retired plumber in Decatur did not arrive at an LVEF of 12% and INTERMACS profile 3 because of bad luck alone. He arrived there because two myocardial infarctions, occurring in a patient without a cardiologist, without ApoB screening, and without statin therapy until after the first MI, destroyed successive portions of his left ventricle. The LVAD is a remarkable engineering solution to a preventable biological failure.

This clinical framework does not promise that every patient who completes a structured cardiovascular assessment will never need an LVAD. It addresses the primary prevention gap: the 40% of patients who have a first MI without any prior cardiovascular risk identification, and the larger group who have known but undertreated risk factors (ApoB above goal, Lp(a) raised, coronary calcium score positive, pre-diabetes with insulin resistance) for whom early, aggressive intervention can prevent the MI that begins the cardiomyopathy trajectory.

For patients already in the advanced heart failure stage, comprehensive preventive cardiology and structured post-implant monitoring provide co-management infrastructure that supplements the LVAD program: medication optimisation review, nutrition and rehabilitation support, and care coordination between the LVAD centre and the patient’s local cardiologist. The LVAD program at a major academic center cannot provide the long-term ongoing relationship that prevents the quality-of-life gaps between quarterly visits. This structure can.

The man from Decatur is waiting for a heart. That wait is exactly the space where coordinated preventive care adds value.

Appendix: Extended Clinical Notes

A.1 Patient Selection Criteria and the MOMENTUM 3 Population

The MOMENTUM 3 trial enrolled patients with advanced heart failure (NYHA class IIIB or IV, LVEF below 25%, on maximal medical therapy or inotrope-dependent) and randomized 1028 patients 1:1 to HeartMate III versus HeartMate II 5 / Solid . The 2-year primary endpoint was a composite of survival free from disabling stroke and reoperation to replace or remove the device. HeartMate III achieved the endpoint in 79% of patients versus 60% in the HeartMate II arm, driven primarily by a near-elimination of pump thrombosis and a 50% reduction in stroke.

Understanding who populated this trial matters for applying the evidence to clinical practice. The mean age was 58 years; 80% were male; 55% were INTERMACS profile 3 (stable on intravenous inotropes), and 21% were INTERMACS profile 4 (resting symptoms but not inotrope-dependent). Very few INTERMACS profile 1 or 2 patients (cardiogenic shock or rapidly deteriorating) were enrolled. This means MOMENTUM 3 provides the strongest evidence for the ambulatory advanced heart failure patient who is deteriorating on medical therapy, not the patient in acute cardiogenic shock in the ICU 5 / Solid . For the latter, the ECMO-to-LVAD bridge strategy operates under separate clinical protocols driven by institutional experience rather than randomized trial data.

The INTERMACS profile system classifies patients from 1 (critical cardiogenic shock) to 7 (advanced NYHA III, no fluid overload). HeartMate III is most strongly supported for INTERMACS profiles 2-4. Profile 1 patients receive HeartMate III when they have been stabilized on short-term MCS (Impella or ECMO) and can tolerate open heart surgery. Profiles 5-7 are not routine LVAD candidates; they receive target medical therapy with reassessment at 3-6 months 5 / Solid .

A.2 Anticoagulation Management and Bleeding Complications

The HeartMate III’s full magnetically levitated rotor eliminates rotor-bearing contact and dramatically reduced pump thrombosis compared to the HeartMate II. However, the device still requires systemic anticoagulation because blood flowing through the pump is exposed to non-physiologic shear stress, and any thrombus forming in the inflow cannula, pump housing, or outflow graft carries catastrophic consequences including stroke and pump failure 5 / Solid .

The standard HeartMate III anticoagulation regimen uses warfarin targeting INR 2.0-3.0, combined with aspirin 81 mg daily. INR monitoring is required every 1-2 weeks initially and monthly once stable. Patients with paroxysmal atrial fibrillation require higher-end INR targets (2.5-3.0). INR above 4.0 is associated with a significantly increased gastrointestinal bleeding risk; INR below 1.8 is associated with increased thromboembolic risk 5 / Solid .

Gastrointestinal bleeding is the most common cause of hospitalization in HeartMate III patients outside of heart failure exacerbation. The mechanism is two-fold: acquired von Willebrand disease (the continuous-flow pump shear stress degrades high-molecular-weight vWF multimers, reducing platelet-mediated hemostasis at mucosal capillaries) and the anticoagulation burden itself 5 / Solid . The HeartMate III’s artificial pulse feature (speed modulation creating 30-bpm artificial pulsatility over the background continuous flow) was designed in part to reduce acquired vWD severity by decreasing the duration of maximum shear stress per cardiac cycle. Registry data show a lower GI bleeding hospitalization rate with HeartMate III compared to HeartMate II 4 / Promising .

At Carle Foundation Hospital in Urbana, HeartMate III patients receive a mandatory anticoagulation management enrollment in the pharmacist-directed anticoagulation clinic. INR targets, dose adjustments, and bleeding surveillance are co-managed by the heart failure team and clinical pharmacy, with the advanced heart failure nurse practitioner serving as the primary coordinator for outpatient bleeding events that do not require emergency department presentation.

A.3 Speed Optimization and Hemodynamic Titration

The HeartMate III operates at a programmed speed measured in revolutions per minute (RPM), typically ranging from 3000 to 9000 RPM in clinical use. Speed selection is not a single decision made at implantation; it requires ongoing titration based on hemodynamic goals, aortic valve opening, degree of left ventricular unloading, and right ventricular performance 4 / Promising .

At low speeds, the LVAD provides less flow support, the aortic valve opens more frequently, and the native LV contributes more to forward flow. This approach, sometimes called partial unloading, preserves aortic valve motion and reduces the risk of aortic insufficiency from long-term commissural fusion. At high speeds, the LVAD provides more flow support but can over-unload the LV, cause the interventricular septum to shift leftward (suction events), and impair right ventricular filling by altering septal geometry 4 / Promising .

Speed optimization is performed using echocardiography and right heart catheterization. Echocardiographic parameters include: aortic valve opening pattern (at least intermittent opening is preferred to prevent aortic valve fusion), interventricular septal position (should remain midline or slightly leftward), and estimated PCWP by Doppler. Right heart catheterization at the time of implant and at 6-8 weeks post-implant provides the gold standard for hemodynamic assessment. At Carle Foundation Hospital, speed optimization echocardiograms are performed at 1 month, 3 months, and 6 months post-implant, with additional studies triggered by any clinical change including new dyspnea, worsening renal function, or change in functional status.

A.4 Right Ventricular Failure After LVAD Implantation

Right ventricular failure following LVAD implantation is the most feared early complication and the leading cause of early LVAD-related mortality that is not device-related. The mechanism is geometric: the LVAD reduces left ventricular volume and pressure, shifting the interventricular septum to the right. If the right ventricle is already dysfunctional, this septal shift reduces RV contractility (loss of septal contribution to RV stroke volume) and may cause the tricuspid annulus to dilate further, worsening tricuspid regurgitation 5 / Solid .

Pre-implant prediction of RV failure uses a combination of imaging and hemodynamic markers. The right ventricular stroke work index (RVSWI = mean PAP x stroke volume) below 0.25 mmHg x L/m2 predicts severe post-LVAD RV failure with approximately 70% sensitivity and 80% specificity. TAPSE (tricuspid annular plane systolic excursion) below 7.5 mm on pre-implant echo is an independent predictor of RV failure requiring post-LVAD inotropes 4 / Promising .

Management of post-LVAD RV failure uses inhaled pulmonary vasodilators (inhaled nitric oxide, inhaled epoprostenol) to reduce RV afterload without systemic hypotension, combined with intravenous inotropes (dobutamine or milrinone). For refractory RV failure despite these measures, temporary right ventricular assist devices including the Impella RP (percutaneous) or CentriMag (surgical) are used as a bridge. The decision to implant a biventricular assist device (BiVAD) configuration (HeartMate III left + CentriMag right) must be made quickly; prolonged RV failure while waiting for the RV to recover leads to multi-organ failure that defeats the purpose of LVAD therapy 4 / Promising .

A.5 Destination Therapy Versus Bridge to Transplant: The Evolving Decision

When LVAD therapy was first established, the clinical framework divided patients into two categories: those awaiting heart transplantation (bridge to transplant, BTT) and those ineligible for transplantation receiving permanent device support (destination therapy, DT). This binary is increasingly obsolete. The reality is a continuous reassessment pathway where a patient implanted as DT may later become transplant-eligible (weight loss, resolution of diabetes, improvement in renal function on LVAD support), and a patient implanted as BTT may die waiting for a transplant or be delisted 5 / Solid .

The 2022 UNOS heart allocation policy changes, which moved from a status 1A/1B/2 framework to a six-level numeric system (status 1-6), significantly changed the relative priority given to LVAD-supported patients waiting for transplantation. LVAD-supported patients are now listed at status 4, unless they develop a device complication (thrombosis, driveline infection, recurrent GI bleeding) that shifts their listing status to status 2. This means stable HeartMate III patients in Illinois may wait 1-2 years for transplantation at centers like Northwestern Memorial and Rush University Medical Center, in contrast to the pre-2018 era when LVAD patients often received transplants within months 5 / Solid .

At Carle Foundation Hospital in Urbana, patients implanted as destination therapy are enrolled in a structured 6-month reassessment protocol that evaluates transplant eligibility. The criteria reviewed include: BMI (target below 35 for transplant eligibility), creatinine (target below 2.0), smoking cessation (minimum 6 months), substance use, and psychosocial stability. Approximately 15-20% of DT patients at Carle are reclassified to BTT status within 12 months of implantation based on improvement in comorbidities while on LVAD support 3 / Early .

A.6 Driveline Exit Site Management and Infection Prevention

The percutaneous driveline is the most vulnerable component of the HeartMate III system. It exits the skin in the left or right upper abdominal quadrant and creates a permanent conduit between the external environment and the internal pump pocket. Driveline infection represents the most common long-term LVAD complication and the most common reason for urgent heart transplantation or device explant 5 / Solid .

The Abbott HeartMate III driveline uses a velour coating in the subcutaneous segment designed to promote tissue ingrowth and reduce the micro-motion at the exit site that allows bacterial tracking. Exit site care protocol involves daily dressing changes with chlorhexidine gluconate solution in the first 3 months (while tissue ingrowth occurs), transitioning to every-other-day care with sterile dry gauze thereafter. Patients are trained to perform their own dressing changes before hospital discharge, with competency demonstration required as a discharge criterion 5 / Solid .

Driveline infections are classified by depth: superficial exit site infection (skin and subcutaneous tissue above the fascial level), deep driveline infection (involving the fascial tunnel), and pump pocket infection (involving the pump housing). Superficial infections are treated with oral antibiotics and intensified local wound care. Deep and pump pocket infections require intravenous antibiotics for 4-6 weeks and surgical debridement; they carry a 30-day mortality of approximately 8% from sepsis and device failure 5 / Solid . At Carle Foundation Hospital, LVAD patients with any sign of exit site infection are seen within 48 hours in the advanced heart failure clinic, with a low threshold for inpatient IV antibiotics if the wound extends below the dermis.

A.7 Alarms, Alert Management, and Patient Education

The HeartMate III generates audible and visual alarms that the patient and caregiver must interpret correctly. Alarm categories include: hazard alarms (require immediate action), advisory alarms (require action within hours), and informational notifications. The most critical hazard alarm is the low flow alarm, which indicates that the pump is not delivering adequate output and may reflect suction event (right ventricle underfilling the LV, causing the inflow cannula to contact the ventricular wall), driveline disconnection, or pump thrombosis 5 / Solid .

Patient and caregiver education for alarm management is a mandatory component of LVAD implantation discharge preparation. The Abbott HeartMate III patient education curriculum requires demonstration of competency in: identifying each alarm by sound and display, determining whether the alarm requires immediate 911 activation versus clinic contact, and performing the driveline disconnection check. At Carle Foundation Hospital, the LVAD patient education program uses simulation-based training in the cardiac device clinic, where patients and caregivers practice on a HeartMate III simulator that generates the full range of alarm types in a supervised environment before discharge 3 / Early . The ability to correctly identify a hazard alarm and respond appropriately is assessed by direct observation and documented in the medical record as a discharge criterion. Patients who cannot demonstrate alarm competency before discharge receive additional supervised practice sessions until the skill is verified, extending the hospital stay if necessary.